查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1803583

全球地塞米松植入市場（按適應症、劑型、材料類型、交付途徑、最終用戶和患者類型）：預測（2025-2030 年）

Dexamethasone Implant Market by Indication, Dosage Form, Material Type, Delivery Route, End Users, Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年地塞米松植入市值為 4.9514 億美元，預計到 2025 年將成長至 5.3099 億美元，複合年成長率為 7.50%，到 2030 年將達到 7.6457 億美元。

主要市場統計數據
預測年份（2024年） 4.9514億美元
基準年（2025年） 5.3099億美元
預測年份（2030年） 7.6457億美元
複合年成長率（%） 7.50%

全面介紹地塞米松植入市場格局，重點在於臨床相關性、市場格局和分析目標

眼科治療的進展凸顯了緩釋性類固醇植入在治療眼後節慢性發炎性疾病的重要性。過去十年，地塞米松植入已成為視網膜疾病治療通訊協定的基石，它透過可控的藥物傳遞減輕了頻繁玻璃體內注射的負擔。隨著人口結構變化和糖尿病的流行，視力障礙的發生率持續上升，了解地塞米松植入的臨床意義和戰略機會變得前所未有的緊迫。

分析技術進步、以病人為中心的創新和監管變革對地塞米松植入市場的影響

生物生物分解性聚合物和精密製造技術的進步從根本上改變了眼部藥物傳遞的軌跡。緩釋性如今利用聚乳酸-乙醇酸共聚物和聚己內酯等突破性技術來控制藥物動力學、增強療效並減少注射頻率。同時，各大地區的監管機構也日益支持這些創新，簡化核准流程，並引進新的上市後監管架構。

國際貿易動態以及 2025 年美國關稅對地塞米松植入供應鏈、定價和相關人員策略的累積影響

2025年美國新關稅的實施，加劇了地塞米松植入供應鏈的複雜性。關鍵生物分解性聚合物的原料成本面臨上漲壓力，迫使製造商重新評估籌資策略，並與供應商協商成本分攤協議。這些發展趨勢也影響著分銷網路內多個接觸點的定價結構，付款人和醫療保健提供者都要求更透明且可證明的價值。

詳細的細分分析顯示，適應症、劑型、材料類型、給藥途徑、最終用戶和患者人口統計數據推動了市場差異化

根據適應症對地塞米松植入空間進行細分，可以揭示黃斑部水腫、非感染性葡萄膜炎和術後發炎中不同的生長載體。在黃斑部水腫患者群中，糖尿病黃斑部水腫和視網膜靜脈阻塞代表著獨特的患者路徑，需要客製化的釋放曲線和給藥方案。同時，非感染性葡萄膜炎受益於持續性皮質類固醇給藥，可減輕發炎復發負擔並改善長期視力結果。術後發炎管理擴大利用植入技術，這些技術可在白內障和玻璃體視網膜手術後提供可預測的抗發炎益處。

全面的區域洞察，重點關注美洲、中東和非洲以及亞太市場的獨特動態和驅動力

在美洲，完善的醫療基礎設施和先進的支付機制支持地塞米松植入的快速普及，尤其是在大型眼科中心。該地區強大的臨床試驗管道和明確的報銷代碼為植入創新創造了成熟的環境。另一方面，拉丁美洲經濟體也提供了成長空間，醫療支出的增加和手術能力的提升正在擴大患者獲得治療的管道。

策略公司概況和競爭格局為塑造地塞米松植入開發和分銷未來的關鍵創新者提供了重要見解

領先的製藥和醫療設備公司正透過對研發、生產和夥伴關係生態系統的策略性投資，加強對地塞米松植入平台的關注。全球公司正透過將其獨特的聚合物科學能力與眼科專業知識相結合，擴大產品系列併提升競爭地位。與委外研發機構和學術中心共同開發契約正在加速下一代製劑的共同開發，確保強力的智慧財產權保護和簡化的監管途徑。

指導產業領導者克服監管挑戰、促進創新、最佳化供應鏈和加強市場定位的可行建議

為了應對錯綜複雜的監管障礙和競爭壓力，行業領導者應優先考慮與監管機構的早期溝通。建立積極的溝通管道可以加快核准速度，並明確上市後的承諾。此外，投資先進的生物相容性材料和智慧傳輸技術，可以使植入產品組合更具差異化，並滿足臨床醫生對精準藥物釋放日益成長的期望。

全面的調查方法，涵蓋資料來源、分析框架、檢驗流程和統計方法，以支持市場研究

本分析採用了混合方法研究設計，結合了一手資料和二手資料。一手資料研究包括對視網膜專家、監管事務專業人員和供應鏈高管的深入訪談，以了解第一線人員對臨床表現、核准流程和物流複雜性的觀點。二手資料研究則提取自同行評審日誌、監管申請、專利資料庫和會議論文集，以建立全面的依證。

一個富有洞察力的結論，總結了地塞米松植入生態系統相關人員的關鍵發現、戰略意義和未來前景

綜上所述，主要研究結果表明，地塞米松植入在緩釋性給藥和先進眼科治療的交叉領域中佔據著重要的地位。突破性的材料創新和以患者為中心的護理模式正在融合，推動其廣泛應用，而關稅方面的不利因素則要求制定靈活的供應鏈策略。細分分析突顯了其臨床應用的廣度，以及根據個別患者情況客製化劑量、材料和給藥方案的需求。

目錄

第1章 引言

第2章 分析方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 臨床指引的變化導致地塞米松植入在視網膜靜脈阻塞治療中的仿單標示外使用量增加。
  • 生物分解性聚合物技術進展改善玻璃體內地塞米松植入的緩釋特性
  • 地塞米松植入在糖尿病黃斑部水腫治療的應用日益廣泛，這是基於現實世界的療效證據
  • 增加對地塞米松植入與抗 VEGF 藥物聯合治療的投資，以協同控制視網膜疾病
  • 隨著生物相似藥地塞米松植入進入主要市場，競爭格局發生變化，對現有產品獨佔性構成挑戰
  • 基於人工智慧的病患反應監測平台實現地塞米松植入的新興個人化給藥通訊協定

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：美國關稅的累積影響（2025年）

8. 地塞米松植入市場（按適應症）

  • 黃斑部水腫
    • 糖尿病黃斑部水腫（DME）
    • 視網膜靜脈阻塞（RVO）
  • 非感染性葡萄膜炎
  • 術後炎症

9. 地塞米松植入市場（按劑型）

  • 0.35毫克植入
  • 0.7毫克植入

第10章地塞米松植入市場（依材料類型）

  • 聚（乳酸-乙醇酸）(PLGA)
  • 聚己內酯（PCL）

11. 地塞米松植入市場（依給藥途徑）

  • 玻璃體內
  • 結膜下

第 12 章 地塞米松植入市場（依最終用戶）

  • 學術研究機構
  • 門診手術中心
  • 醫院
  • 眼科診所

13. 地塞米松植入市場（依病患類型）

  • 成人
  • 老年人
  • 孩子們

14.美洲地塞米松植入市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲地塞米松植入市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16. 亞太地塞米松植入市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 市場佔有率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭情境分析
    • AbbVie Inc.
    • 3S Corporation
    • Santen Pharmaceutical Co., Ltd.
    • GNH India Pharmaceuticals Limited.
    • Mehan Healthcare Private Limited.

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-537DB9F46DC6

The Dexamethasone Implant Market was valued at USD 495.14 million in 2024 and is projected to grow to USD 530.99 million in 2025, with a CAGR of 7.50%, reaching USD 764.57 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 495.14 million
Estimated Year [2025] USD 530.99 million
Forecast Year [2030] USD 764.57 million
CAGR (%) 7.50%

Comprehensive Introduction to the Dexamethasone Implant Landscape Emphasizing Clinical Relevance, Market Context and Analysis Objectives

The evolution of ocular therapeutics has underscored the significance of sustained-release steroid implants in addressing chronic inflammatory conditions of the posterior segment. Over the past decade, dexamethasone implants have emerged as a cornerstone of treatment protocols for retinal disorders, offering controlled drug delivery that mitigates the burdens of frequent intravitreal injections. As demographic shifts and the prevalence of diabetes continue to intensify the incidence of visual impairment, understanding the clinical implications and strategic opportunities surrounding dexamethasone implants has never been more urgent.

This executive overview sets forth the foundational context for evaluating the therapeutic, regulatory, and commercial dimensions of dexamethasone intravitreal implants. By outlining the clinical rationale for sustained-release corticosteroid delivery, this introduction positions stakeholders to appreciate the nuanced interplay between emerging material sciences, delivery modalities, and patient adherence considerations. It also delineates the overarching goals of the analysis: to inform strategic planning, guide resource allocation, and illuminate pathways for innovation.

In highlighting the scope of this research, emphasis is placed on synthesizing current scientific consensus, regulatory developments, and competitive intelligence. This initial section anchors the reader in the critical drivers of the dexamethasone implant market and establishes the framework for subsequent sections that will explore transformative shifts, tariff impacts, segmentation insights, regional dynamics, corporate strategies, and actionable recommendations.

Analysis of Transformative Shifts Reshaping the Dexamethasone Implant Market Through Technological Advances, Patient-Centric Innovations, and Regulatory Evolutions

Advances in biodegradable polymers and precision manufacturing have fundamentally altered the trajectory of ocular drug delivery. Sustained-release formulations now leverage breakthroughs in poly(lactic-co-glycolic acid) and polycaprolactone technologies to orchestrate controlled pharmacokinetics, elevating therapeutic efficacy and reducing injection frequency. Concurrently, regulatory agencies across major territories have increasingly endorsed these innovations, streamlining approval timelines while introducing novel post-marketing surveillance frameworks.

Patient engagement platforms and digital imaging tools have likewise catalyzed a shift toward patient-centric care models, enabling real-time monitoring of implant performance and adverse events. These developments align with a broader healthcare ecosystem that prioritizes value-based outcomes and evidence-driven reimbursement. As integrated diagnostics become more prevalent, ophthalmologists and retina specialists are equipped to tailor interventions based on predictive biomarkers, further enhancing the clinical utility of dexamethasone implants.

In response to these converging trends, manufacturers are forging collaborations with medical technology firms and academic research centers. Such alliances drive iterative improvements in implant design, enhance biocompatibility, and foster the integration of smart delivery systems. Consequently, the dexamethasone implant sector is undergoing a transformative recalibration that extends beyond product innovation to encompass regulatory strategy, patient engagement, and cross-sector partnerships.

International Trade Dynamics and the Cumulative Impact of 2025 United States Tariffs on Dexamethasone Implant Supply Chains, Pricing, and Stakeholder Strategies

The implementation of new United States tariff measures in 2025 has introduced a layer of complexity across the dexamethasone implant supply chain. Raw material costs for key biodegradable polymers have experienced upward pressure, prompting manufacturers to reassess sourcing strategies and negotiate cost-sharing agreements with suppliers. These dynamics have, in turn, influenced pricing structures at multiple junctures within the distribution network, with payers and providers demanding greater transparency and demonstrable value.

Moreover, the tariff environment has underscored the importance of regional manufacturing hubs in mitigating exposure to cross-border levies. Several leading implant producers have accelerated investment in domestic production capacity, leveraging advanced polymer processing facilities to secure supply security. At the same time, alternative routes for polymer synthesis and localized partnerships with contract development and manufacturing organizations have emerged as viable strategies to insulate margins.

Stakeholders must also navigate evolving customs protocols and compliance requirements, which now feature enhanced reporting obligations and risk assessments for medical devices. In response, industry participants are reinforcing their regulatory affairs teams and deploying digital trade management platforms to streamline tariff classification and duty mitigation. Through these collective efforts, companies can preserve innovation incentives while maintaining competitive positioning in a tariff-impacted landscape.

In-Depth Segment Analysis Revealing How Indication, Dosage Form, Material Type, Delivery Route, End Users, and Patient Demographics Drive Market Differentiation

Segmenting the dexamethasone implant arena by indication reveals differentiated growth vectors across macular edema, non-infectious uveitis, and post-operative inflammation. Within the macular edema cohort, diabetic macular edema and retinal vein occlusion present unique patient pathways, each demanding tailored release profiles and dosing regimens. Meanwhile, the non-infectious uveitis segment benefits from sustained corticosteroid coverage, reducing the burden of recurrent inflammation and improving long-term visual outcomes. Post-operative inflammation management further leverages implant technology to deliver predictable anti-inflammatory effects following cataract or vitreoretinal surgeries.

Dosage form variations, namely 0.35 milligram and 0.7 milligram implants, allow clinicians to align therapy intensity with disease severity and patient tolerance. Lower-dose implants offer a favorable safety profile for mild to moderate cases, whereas higher-dose configurations are preferred when robust, extended-release activity is required. Material composition also plays a pivotal role; poly(lactic-co-glycolic acid) formulations enable rapid polymer breakdown and drug release, while polycaprolactone matrices afford slower degradation and prolonged therapeutic exposure.

Delivery route options add another dimension of customization, with intravitreal administration remaining the standard of care but emerging interest in subconjunctival approaches for anterior segment applications. End-user preferences within academic research institutes, ambulatory surgical centers, hospitals, and ophthalmic clinics shape adoption curves and influence training priorities. Patient demographics-across adult, geriatric, and pediatric groups-further dictate tolerability assessments and inform the development of pediatric-friendly implant variants. Collectively, these segmentation insights illuminate the multifaceted decision drivers that underpin product differentiation and clinical adoption.

Comprehensive Regional Insights Highlighting the Unique Dynamics and Growth Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific Markets

In the Americas, established healthcare infrastructures and advanced payment mechanisms support rapid uptake of dexamethasone implants, particularly within leading ophthalmology centers. The region's robust pipeline of clinical trials and well-defined reimbursement codes underpin a mature environment for implant innovations. Conversely, economies within Latin America present pockets of growth, where rising healthcare expenditure and expanding surgical capacity are broadening patient access.

Within Europe, Middle East & Africa, variances in regulatory frameworks and reimbursement pathways create a mosaic of market conditions. Western European countries, bolstered by centralized approval processes and coordinated pricing negotiations, serve as early adopters of next-generation biodegradable implants. In contrast, emerging markets in the Middle East and parts of Africa are characterized by nascent clinical infrastructure and evolving procurement protocols, presenting both challenges and opportunities for tailored market entry strategies.

Asia-Pacific exhibits dynamic expansion driven by demographic trends, increasing incidence of diabetic complications, and government initiatives to strengthen ophthalmic care. Rapidly developing healthcare sectors in China and India are prioritizing capacity building in retinal services, while mature markets like Japan maintain rigorous regulatory standards that align closely with global best practices. These regional variances underscore the imperative for localized engagement models and flexible commercialization plans.

Strategic Company Profiles and Competitive Landscapes Offering Critical Insights into Leading Innovators Shaping the Future of Dexamethasone Implant Development and Distribution

Leading pharmaceutical and medical device companies are intensifying their focus on dexamethasone implant platforms through strategic investments in research, manufacturing, and partnership ecosystems. Global players have expanded their product portfolios by integrating proprietary polymer science capabilities with ophthalmology expertise, thereby enhancing their competitive moats. Collaboration agreements with contract development organizations and academic centers have accelerated the co-development of next-generation formulations, ensuring robust intellectual property protection and streamlined regulatory pathways.

Mid-sized and specialized biotech firms are carving out niches by capitalizing on novel delivery modalities and patient engagement technologies. These entities often pursue licensing deals and distribution partnerships to extend their geographic reach and access complementary channels. Meanwhile, established implant manufacturers are reinforcing their global distribution networks, optimizing cold-chain logistics, and deploying digital platforms to facilitate order management and end-to-end traceability.

Across the competitive landscape, a recurring emphasis on lifecycle management strategies reflects the drive to differentiate through incremental formulation tweaks and novel dosage strengths. These approaches are supported by real-world evidence studies and post-market surveillance initiatives that quantify long-term safety and adherence benefits. Through these collective efforts, key companies are shaping the future trajectory of dexamethasone implant innovation and commercialization.

Actionable Recommendations to Guide Industry Leaders Through Regulatory Challenges, Foster Innovation, Optimize Supply Chains, and Strengthen Market Positioning

To navigate the complex interplay of regulatory hurdles and competitive pressures, industry leaders should prioritize early engagement with regulatory authorities. Establishing proactive communication channels can expedite approval timelines and clarify evolving post-marketing commitments. Further, investing in advanced biocompatible materials and smart delivery technologies will differentiate implant portfolios and meet rising clinician expectations for precision drug release.

Optimizing supply chain resilience demands diversification of raw material sources and the establishment of regional manufacturing footprints. Embracing strategic partnerships with contract manufacturers in key geographies can mitigate tariff exposure and enhance production flexibility. Simultaneously, integrating digital trade management platforms will streamline compliance and reduce administrative risk.

Finally, engaging patients and providers through tailored educational programs and digital adherence tools will reinforce value propositions and drive favorable reimbursement negotiations. By leveraging real-world outcomes data and patient-reported experience metrics, companies can underscore the clinical and economic benefits of sustained-release dexamethasone implants, thereby reinforcing their standing within formulary discussions and treatment guidelines.

Comprehensive Research Methodology Covering Data Sources, Analytical Frameworks, Validation Processes, and Statistical Techniques Supporting the Market Study

This analysis employed a mixed-methods research design combining primary and secondary data sources. Primary insights were obtained through in-depth interviews with retina specialists, regulatory affairs experts, and supply chain executives to capture frontline perspectives on clinical performance, approval processes, and logistical complexities. Secondary research drew from peer-reviewed journals, regulatory filings, patent databases, and conference proceedings to construct a comprehensive evidence base.

Data triangulation techniques were applied to validate qualitative findings against quantitative indicators, ensuring consistency and reliability. Key variables such as polymer degradation rates, dosage efficacy benchmarks, and price trend analyses were subjected to sensitivity testing to highlight scenario-based impacts. Ethical standards and data integrity protocols were strictly observed, with all proprietary sources anonymized to maintain confidentiality.

Analytical frameworks incorporated SWOT assessments, competitive benchmarking, and PESTEL analysis to contextualize market drivers and barriers. Advanced statistical tools were leveraged for trend analysis, while visual dashboards facilitated clear interpretation of complex datasets. This rigorous methodology underpins the credibility of the strategic insights and recommendations presented herein.

Insightful Conclusion Summarizing Key Findings, Strategic Implications, and Future Outlook for Stakeholders in the Dexamethasone Implant Ecosystem

In synthesizing the key findings, it is evident that dexamethasone implants occupy a critical niche at the intersection of sustained-release drug delivery and advanced ophthalmic therapy. Transformative material innovations and patient-centric care models are coalescing to drive adoption, even as tariff headwinds necessitate agile supply chain strategies. The segmentation analysis underscores the breadth of clinical applications and the need for tailored dosing, material, and delivery options to address distinct patient profiles.

Regional dynamics reveal the importance of localized regulatory and reimbursement engagements, with each geography presenting unique enablers and constraints. Competitive landscapes are marked by strategic alliances and lifecycle management initiatives, reflecting the high stakes of capturing value in this evolving space. Accordingly, industry participants must align their R&D investments, manufacturing footprints, and commercial approaches with these multifaceted imperatives.

Looking ahead, the convergence of real-world evidence, digital health integrations, and advanced polymer science will define the next frontier of dexamethasone implant innovation. Stakeholders who proactively embrace these themes will be best positioned to shape clinical practice, secure favorable policy outcomes, and drive long-term growth in this vital segment of ophthalmic care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing off-label applications for dexamethasone implants in retinal vein occlusion management due to shifting clinical guidelines
  • 5.2. Advances in biodegradable polymer technologies improving sustained-release profiles of dexamethasone intravitreal implants
  • 5.3. Increasing adoption of dexamethasone implant in diabetic macular edema treatment driven by real-world evidence of efficacy
  • 5.4. Rising investment in combination therapies integrating dexamethasone implants with anti-VEGF agents for synergistic retinal disease control
  • 5.5. Competitive landscape shift as biosimilar dexamethasone implants enter key markets challenging established product exclusivity
  • 5.6. Emergence of personalized dosing protocols for dexamethasone implants enabled by AI-based patient response monitoring platforms

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Dexamethasone Implant Market, by Indication

  • 8.1. Introduction
  • 8.2. Macular Edema
    • 8.2.1. Diabetic Macular Edema (DME)
    • 8.2.2. Retinal Vein Occlusion (RVO)
  • 8.3. Non-Infectious Uveitis
  • 8.4. Post-Operative Inflammation

9. Dexamethasone Implant Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. 0.35 mg Implants
  • 9.3. 0.7 mg Implants

10. Dexamethasone Implant Market, by Material Type

  • 10.1. Introduction
  • 10.2. Poly(lactic-co-glycolic acid) (PLGA)
  • 10.3. Polycaprolactone (PCL)

11. Dexamethasone Implant Market, by Delivery Route

  • 11.1. Introduction
  • 11.2. Intravitreal
  • 11.3. Subconjunctival

12. Dexamethasone Implant Market, by End Users

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Ambulatory Surgical Centers
  • 12.4. Hospitals
  • 12.5. Ophthalmic Clinics

13. Dexamethasone Implant Market, by Patient Type

  • 13.1. Introduction
  • 13.2. Adult
  • 13.3. Geriatric
  • 13.4. Pediatric

14. Americas Dexamethasone Implant Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Dexamethasone Implant Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Dexamethasone Implant Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. 3S Corporation
    • 17.3.3. Santen Pharmaceutical Co., Ltd.
    • 17.3.4. GNH India Pharmaceuticals Limited.
    • 17.3.5. Mehan Healthcare Private Limited.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. DEXAMETHASONE IMPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. DEXAMETHASONE IMPLANT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. DEXAMETHASONE IMPLANT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. DEXAMETHASONE IMPLANT MARKET: RESEARCHAI
  • FIGURE 28. DEXAMETHASONE IMPLANT MARKET: RESEARCHSTATISTICS
  • FIGURE 29. DEXAMETHASONE IMPLANT MARKET: RESEARCHCONTACTS
  • FIGURE 30. DEXAMETHASONE IMPLANT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. DEXAMETHASONE IMPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DIABETIC MACULAR EDEMA (DME), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DIABETIC MACULAR EDEMA (DME), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY RETINAL VEIN OCCLUSION (RVO), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY RETINAL VEIN OCCLUSION (RVO), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY NON-INFECTIOUS UVEITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY NON-INFECTIOUS UVEITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POST-OPERATIVE INFLAMMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POST-OPERATIVE INFLAMMATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.35 MG IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.35 MG IMPLANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.7 MG IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.7 MG IMPLANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLY(LACTIC-CO-GLYCOLIC ACID) (PLGA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLY(LACTIC-CO-GLYCOLIC ACID) (PLGA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INTRAVITREAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY SUBCONJUNCTIVAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY SUBCONJUNCTIVAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 93. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 94. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 95. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 96. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 107. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 108. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 109. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 110. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 123. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 124. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 128. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 135. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 136. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 137. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 138. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 139. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 142. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 143. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 144. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 179. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 180. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 181. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 182. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 183. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 186. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 187. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 188. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 189. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 193. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 194. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 195. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 196. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 197. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 200. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 201. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 202. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 203. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 207. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 208. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 209. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 210. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 211. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 214. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 215. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 216. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 217. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 221. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 222. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 223. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 225. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 229. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 230. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 231. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 235. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 236. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 237. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 238. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 239. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 242. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 243. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 245. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 262. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 263. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 264. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 265. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 266. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 267. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 270. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 272. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 278. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 280. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 284. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 286. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 291. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 292. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 293. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 294. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 295. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 298. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 299. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 300. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 301. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 305. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 306. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 307. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 308. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 309. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 312. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 313. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 314. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 318. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 319. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 320. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 321. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 322. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 323. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 325. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 326. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 327. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 328. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 329. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 331. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 333. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 334. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLI